Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 7,762 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: High Grade Clear all
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 20, 2026, 5:34 AM EDT
Not listed Not applicable Interventional

Reading Remediation and Outcomes in Detention

NCT03261076
View directory record Official record
Conditions
Specific Learning Disorder (MeSH Unique ID: D000067559), Dyslexia (MeSH Unique ID: D004410), Conduct Disorder (MeSH Unique ID: D019955)
Interventions
Strategies Enhancing Reading in Older Underperf. Students
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Years to 16 Years · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine

NCT01084291
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for DEN1, Placebo injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Phase 4 Interventional

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

NCT02537691
View directory record Official record
Conditions
Asthma
Interventions
FP, LABA, LTRA, LAMA, Theophylline, Oral Corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 20, 2026, 5:34 AM EDT
Withdrawn Phase 3 Interventional

Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients

NCT03968640
View directory record Official record
Conditions
Multiple Organ Failure
Interventions
CoQ10, Placebo
Dietary Supplement
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention

NCT04760652
View directory record Official record
Conditions
Depression and Suicide
Interventions
Cognitive Behavioral Therapy CBT, TAU
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • New Haven, Connecticut • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

NCT01854047
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

NCT00045708
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
ixabepilone, pharmacological study, Anticonvulsant
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 20, 2026, 5:34 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

NCT07133308
View directory record Official record
Conditions
Alopecia Areata
Interventions
Deuruxolitinib, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH

NCT02412540
View directory record Official record
Conditions
Obesity, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Interventions
Comprehensive Lifestyle Intervention
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 19 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia

NCT00260689
View directory record Official record
Conditions
Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia
Interventions
Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine, Alemtuzumab
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

NCT01442038
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
2,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 20, 2026, 5:34 AM EDT
Withdrawn Phase 1 Interventional

Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)

NCT03895658
View directory record Official record
Conditions
Unipolar Depression
Interventions
MRI, MagPro TMS stimulator and coil, Thymatron (R) System IV paired with 4X1 HDECT
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
22 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)

NCT02176226
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety Disorders
Interventions
IntelliCare
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
19 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 20, 2026, 5:34 AM EDT
Not yet recruiting Not applicable Interventional

Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Fetuses With Severe CDH

NCT07767825
View directory record Official record
Conditions
Severe Congenital Diaphragmatic Hernia
Interventions
Goldballoon Detachable Balloon (GOLDBAL2)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

NCT00889538
View directory record Official record
Conditions
Autism, Severe Behavior Disorder
Interventions
placebo, glutathione, glutathione, vit C and NAC
Drug
Lead sponsor
University of Louisville
Other
Eligibility
5 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 20, 2026, 5:34 AM EDT
Recruiting No phase listed Observational

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Comparing Therapies for the Treatment of Severe Aplastic Anemia

NCT00001626
View directory record Official record
Conditions
Severe Aplastic Anemia (SAA)
Interventions
antithymocyte globulin, cyclophosphamide, cyclosporine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
15 Years to 110 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 20, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional Results available

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

NCT03610048
View directory record Official record
Conditions
Refractory Major Depressive Disorder
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 20, 2026, 5:34 AM EDT
Recruiting Phase 4 Interventional

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

NCT07058155
View directory record Official record
Conditions
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
Procedure · Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Phase 3 Interventional

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

NCT05552326
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
63
States / cities
Birmingham, Alabama • Peoria, Arizona • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 20, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

NCT01393626
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
73
States / cities
Anaheim, California • Oceanside, California • Poway, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 20, 2026, 5:34 AM EDT
Withdrawn Phase 2 Interventional

Allograft for Sickle Cell Disease and Thalassemia

NCT02038478
View directory record Official record
Conditions
Sickle Cell Disease and Thalassemia
Interventions
Donor Stem Cell Transplantation
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 20, 2026, 5:34 AM EDT